- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 909613, 15 pages
Inflammatory Bowel Disease Therapies and Gut Function in a Colitis Mouse Model
1School of Women’s and Children’s Health, University of New South Wales, Randwick, Sydney, NSW 2031, Australia
2School of Biotechnology and Biomolecular Sciences, University of New South Wales, Randwick, Sydney, NSW 2052, Australia
3Department of Gastroenterology, Sydney Children’s Hospital, Randwick, Sydney, NSW 2031, Australia
4Department of Pathology, Institute of Veterinary, Animal and Biomedical Sciences, Massey University, Palmerston North 4442, New Zealand
5Paediatric Gastroenterology, Christchurch Hospital, Christchurch 8140, New Zealand
6Department of Paediatrics, University of Otago, Christchurch, Christchurch 8140, New Zealand
Received 30 April 2013; Revised 1 July 2013; Accepted 1 July 2013
Academic Editor: David Bernardo
Copyright © 2013 Lily Nahidi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- C. Förster, “Tight junctions and the modulation of barrier function in disease,” Histochemistry and Cell Biology, vol. 130, no. 1, pp. 55–70, 2008.
- S. Zeissig, N. Bürgel, D. Günzel et al., “Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease,” Gut, vol. 56, no. 1, pp. 61–72, 2007.
- B. K. Reuter and T. T. Pizarro, “Mechanisms of tight junction dysregulation in the SAMP1YitFc model of crohn's disease-like ileitis,” Annals of the New York Academy of Sciences, vol. 1165, pp. 301–307, 2009.
- N. S. H. de Jong, S. T. Leach, and A. S. Day, “Fecal S100A12: a novel noninvasive marker in children with Crohn's disease,” Inflammatory Bowel Diseases, vol. 12, no. 7, pp. 566–572, 2006.
- R. K. Linskens, X. W. Huijsdens, P. H. M. Savelkoul, C. M. J. E. Vandenbrouckc-Grauls, and S. G. M. Meuwissen, “The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics,” Scandinavian Journal of Gastroenterology, vol. 36, Supplement, no. 234, pp. 29–40, 2001.
- C. Fiocchi, “Inflammatory bowel disease: etiology and pathogenesis,” Gastroenterology, vol. 115, no. 1, pp. 182–205, 1998.
- M. G. Laukoetter, P. Nava, and A. Nusrat, “Role of the intestinal barrier in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 14, no. 3, pp. 401–407, 2008.
- J. G. Fox, Z. Ge, M. T. Whary, S. E. Erdman, and B. H. Horwitz, “Helicobacter hepaticus infection in mice: models for understanding lower bowel inflammation and cancer,” Mucosal Immunology, vol. 4, no. 1, pp. 22–30, 2011.
- K. L. Madsen, J. S. Doyle, L. D. Jewell, M. M. Tavernini, and R. N. Fedorak, “Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice,” Gastroenterology, vol. 116, no. 5, pp. 1107–1114, 1999.
- M. T. Whary, S. J. Danon, Y. Feng et al., “Rapid onset of ulcerative typhlocolitis in B6.129P2-IL10tm1Cgn (IL-10-/-) mice infected with Helicobacter trogontum is associated with decreased colonization by altered Schaedler's flora,” Infection and Immunity, vol. 74, no. 12, pp. 6615–6623, 2006.
- J. O. Lindsay and H. J. F. Hodgson, “Review article: the immunoregulatory cytokine interleukin-10: a therapy for Crohn's disease?” Alimentary Pharmacology and Therapeutics, vol. 15, no. 11, pp. 1709–1716, 2001.
- M. B. Ye, J. P. Bak, C. S. An et al., “Dietary β-glucan regulates the levels of inflammatory factors, inflammatory cytokines, and immunoglobulins in interleukin-10 knockout mice,” Journal of Medicinal Food, vol. 14, no. 5, pp. 468–474, 2011.
- E. N. Mendes, D. M. M. Queiroz, F. E. Dewhirst, B. J. Paster, S. B. Moura, and J. G. Fox, “Helicobacter trogontum sp. nov., isolated from the rat intestine,” International Journal of Systematic Bacteriology, vol. 46, no. 4, pp. 916–921, 1996.
- S. B. Moura, E. N. Mendes, D. M. M. Queiroz et al., “Microbiological and histological study of the gastrointestinal tract of germ-free mice infected with Helicobacter trogontum,” Research in Microbiology, vol. 150, no. 3, pp. 205–212, 1999.
- Z. Shen, Y. Feng, A. B. Rogers et al., “Cytolethal distending toxin promotes Helicobacter cinaedi-associated typhlocolitis in interleukin-10-deficient mice,” Infection and Immunity, vol. 77, no. 6, pp. 2508–2516, 2009.
- C. L. Franklin, P. L. Gorelick, L. K. Riley et al., “Helicobacter typhlonius sp. nov., a novel murine urease-negative Helicobacter species,” Journal of Clinical Microbiology, vol. 39, no. 11, pp. 3920–3926, 2001.
- N. O. Kaakoush, A. Sirianni, M. J. Raftery, et al., “The secretome of Helicobacter trogontum,” Helicobacter, vol. 18, no. 4, pp. 316–320, 2013.
- L. Zhang, A. Day, G. McKenzie, and H. Mitchell, “Nongastric Helicobacter species detected in the intestinal tract of children,” Journal of Clinical Microbiology, vol. 44, no. 6, pp. 2276–2279, 2006.
- S. M. Man, L. Zhang, A. S. Day, S. Leach, and H. Mitchell, “Detection of enterohepatic and gastric Helicobacter species in fecal specimens of children with crohn's disease,” Helicobacter, vol. 13, no. 4, pp. 234–238, 2008.
- E. Miyauchi, H. Morita, J. Okuda, T. Sashihara, M. Shimizu, and S. Tanabe, “Cell wall fraction of Enterococcus hirae ameliorates TNF-α-induced barrier impairment in the human epithelial tight junction,” Letters in Applied Microbiology, vol. 46, no. 4, pp. 469–476, 2008.
- L. Kruidenier and H. W. Verspaget, “Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease: radicals or ridiculous?” Alimentary Pharmacology and Therapeutics, vol. 16, no. 12, pp. 1997–2015, 2002.
- A. S. Day, K. E. Whitten, and N. S. H. de Jong, “Nutrition and nutritional management of Crohn's disease in children and adolescents,” Current Nutrition and Food Science, vol. 2, no. 1, pp. 3–13, 2006.
- R. Berni Canani, G. Terrin, O. Borrelli et al., “Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease,” Digestive and Liver Disease, vol. 38, no. 6, pp. 381–387, 2006.
- A. Harris, E. R. Feller, and S. A. Shah, “Medical therapy of IBD in 2009,” Medicine and Health, Rhode Island, vol. 92, no. 3, pp. 78–81, 2009.
- G. Van Assche, S. Vermeire, and P. Rutgeerts, “Mucosal healing and anti TNFs in IBD,” Current Drug Targets, vol. 11, no. 2, pp. 227–233, 2010.
- P. Rutgeerts, S. Vermeire, and G. Van Assche, “Biological therapies for inflammatory bowel diseases,” Gastroenterology, vol. 136, no. 4, pp. 1182–1197, 2009.
- M. Ferrante and G. Van Assche, “Medical therapy and mucosal healing,” Current Drug Targets, vol. 13, no. 10, pp. 1294–1299, 2012.
- A. S. Day, K. E. Whitten, M. Sidler, and D. A. Lemberg, “Systematic review: nutritional therapy in paediatric Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 4, pp. 293–307, 2008.
- A. Papa, G. Mocci, F. Scaldaferri et al., “New therapeutic approach in inflammatory bowel disease,” European Review for Medical and Pharmacological Sciences, vol. 13, supplement 1, pp. 33–35, 2009.
- C. Thukral, W. J. Travassos, and M. A. Peppercorn, “The role of antibiotics in inflammatory bowel disease,” Current Treatment Options in Gastroenterology, vol. 8, no. 3, pp. 223–228, 2005.
- T. Ishikawa, S. Okamura, H. Oshimoto, R. Kobayashi, and M. Mori, “Metronidazole plus ciprofloxacin therapy for active Crohn's disease,” Internal Medicine, vol. 42, no. 4, pp. 318–321, 2003.
- K. L. Madsen, J. S. Doyle, M. M. Tavernini, L. D. Jewell, R. P. Rennie, and R. N. Fedorak, “Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice,” Gastroenterology, vol. 118, no. 6, pp. 1094–1105, 2000.
- S. Colpaert, Z. Liu, B. De Greef, P. Rutgeerts, J. L. Ceuppens, and K. Geboes, “Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 11, pp. 1827–1836, 2001.
- L. Sutherland, J. Singleton, J. Sessions et al., “Double blind, placebo controlled trial of metronidazole in Crohn's disease,” Gut, vol. 32, no. 9, pp. 1071–1075, 1991.
- J.-F. Colombel, M. Lémann, M. Cassagnou et al., “A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease,” The American Journal of Gastroenterology, vol. 94, no. 3, pp. 674–678, 1999.
- B. Shen, J.-P. Achkar, B. A. Lashner et al., “A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis,” Inflammatory Bowel Diseases, vol. 7, no. 4, pp. 301–305, 2001.
- Y.-X. Yang and G. R. Lichtenstein, “Corticosteroids in Crohn's disease,” The American Journal of Gastroenterology, vol. 97, no. 4, pp. 803–823, 2002.
- T. J. Creed and C. S. J. Probert, “Review article: steroid resistance in inflammatory bowel disease: mechanisms and therapeutic strategies,” Alimentary Pharmacology and Therapeutics, vol. 25, no. 2, pp. 111–122, 2007.
- O. Borrelli, L. Cordischi, M. Cirulli et al., “Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial,” Clinical Gastroenterology and Hepatology, vol. 4, no. 6, pp. 744–753, 2006.
- R. M. Beattie, “Nutritional management of Crohn's disease in childhood,” Journal of the Royal Society of Medicine, vol. 91, no. 3, pp. 135–137, 1998.
- M. H. Alhagamhmad, A. S. Day, D. A. Lemberg, et al., “An update of the role of nutritional therapy in the management of Crohn's disease,” Journal of Gastroenterology, vol. 47, no. 8, pp. 872–882, 2012.
- N. S. H. de Jong, S. T. Leach, and A. S. Day, “Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation,” Digestive Diseases and Sciences, vol. 52, no. 9, pp. 2029–2036, 2007.
- E. J. Breese, C. A. Michie, S. W. Nicholls et al., “Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease,” Gastroenterology, vol. 106, no. 6, pp. 1455–1466, 1994.
- J. M. E. Fell, M. Paintin, F. Arnaud-Battandieri et al., “Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 14, no. 3, pp. 281–289, 2000.
- L. Nahidi, A. S. Day, D. A. Lemberg, and S. T. Leach, “Differential effects of nutritional and non-nutritional therapies on intestinal barrier function in an in vitro model,” Journal of Gastroenterology, vol. 47, no. 2, pp. 107–117, 2012.
- K. Lewis, J. Caldwell, V. Phan et al., “Decreased epithelial barrier function evoked by exposure to metabolic stress and nonpathogenic E. coli is enhanced by TNF-α,” The American Journal of Physiology, vol. 294, no. 3, pp. G669–G678, 2008.
- J. Santos, D. Yates, M. Guilarte, M. Vicario, C. Alonso, and M. H. Perdue, “Stress neuropeptides evoke epithelial responses via mast cell activation in the rat colon,” Psychoneuroendocrinology, vol. 33, no. 9, pp. 1248–1256, 2008.
- A. A. Teitelbaum, M. G. Gareau, J. Jury, C. Y. Ping, and M. H. Perdue, “Chronic peripheral administration of corticotropin-releasing factor causes colonic barrier dysfunction similar to psychological stress,” The American Journal of Physiology, vol. 295, no. 3, pp. G452–G459, 2008.
- A. J. Kiliaan, P. R. Saunders, P. B. Bijlsma et al., “Stress stimulates transepithelial macromolecular uptake in rat jejunum,” The American Journal of Physiology, vol. 275, no. 5, pp. G1037–G1044, 1998.
- F. Wang, W. V. Graham, Y. Wang, E. D. Witkowski, B. T. Schwarz, and J. R. Turner, “Interferon-γ and tumor necrosis factor-α synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression,” The American Journal of Pathology, vol. 166, no. 2, pp. 409–419, 2005.
- T. Y. Ma, M. A. Boivin, D. Ye, A. Pedram, and H. M. Said, “Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression,” The American Journal of Physiology, vol. 288, no. 3, pp. G422–G430, 2005.
- D. R. Trune, R. J. Wobig, J. B. Kempton, and S. H. Hefeneider, “Steroid treatment in young MRL.MpJ-Fas(lpr) autoimmune mice prevents cochlear dysfunction,” Hearing Research, vol. 137, no. 1-2, pp. 167–173, 1999.
- M. Cecilia Berin, P.-C. Yang, L. Ciok, S. Waserman, and M. H. Perdue, “Role for IL-4 in macromolecular transport across human intestinal epithelium,” The American Journal of Physiology, vol. 276, no. 5, pp. C1046–C1052, 1999.
- J. L. Johnson, H. Hong, J. Monfregola, and S. D. Catz, “Increased survival and reduced Neutrophil infiltration of the liver in rab27a- but not munc13-4-deficient mice in Lipopolysaccharide-induced systemic inflammation,” Infection and Immunity, vol. 79, no. 9, pp. 3607–3618, 2011.
- A.-K. Tide, T. Sjögren, M. Svensson et al., “2-Thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation,” Journal of Biological Chemistry, vol. 286, no. 43, pp. 37578–37589, 2011.
- X. Sun, H. Yang, K. Nose et al., “Decline in intestinal mucosal IL-10 expression and decreased intestinal barrier function in a mouse model of total parenteral nutrition,” The American Journal of Physiology, vol. 294, no. 1, pp. G139–G147, 2007.
- A. A. A. Blanchard, P. H. Watson, R. P. C. Shiu et al., “Differential expression of claudin 1, 3, and 4 during normal mammary gland development in the mouse,” DNA and Cell Biology, vol. 25, no. 2, pp. 79–86, 2006.
- G. Zhi, J. W. Ryder, J. Huang et al., “Myosin light chain kinase and myosin phosphorylation effect frequency-dependent potentiation of skeletal muscle contraction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 48, pp. 17519–17524, 2005.
- M. J. Ruddy, F. Shen, J. B. Smith, A. Sharma, and S. L. Gaffen, “Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment,” Journal of Leukocyte Biology, vol. 76, no. 1, pp. 135–144, 2004.
- K. L. Brewer and T. A. Nolan, “Spinal and supraspinal changes in tumor necrosis factor-α expression following excitotoxic spinal cord injury,” Journal of Molecular Neuroscience, vol. 31, no. 1, pp. 13–21, 2007.
- P. Pulimeno, C. Bauer, J. Stutz, and S. Citi, “PLEKHA7 is an adherens junction protein with a tissue distribution and subcellular localization distinct from ZO-1 and E-Cadherin,” PLoS ONE, vol. 5, no. 8, Article ID e12207, 2010.
- K. L. Edelblum and J. R. Turner, “The tight junction in inflammatory disease: communication breakdown,” Current Opinion in Pharmacology, vol. 9, no. 6, pp. 715–720, 2009.
- P. Henderson, J. E. Van Limbergen, J. Schwarze, and D. C. Wilson, “Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 17, no. 1, pp. 382–395, 2011.
- G. Roda, A. Sartini, E. Zambon et al., “Intestinal epithelial cells in inflammatory bowel diseases,” World Journal of Gastroenterology, vol. 16, no. 34, pp. 4264–4271, 2010.
- C. R. Weber and J. R. Turner, “Inflammatory bowel disease: is it really just another break in the wall?” Gut, vol. 56, no. 1, pp. 6–8, 2007.
- P. R. Gibson, “Increased gut permeability in Crohn's disease: is TNF the link?” Gut, vol. 53, no. 12, pp. 1724–1725, 2004.
- H. S. Oz, M. Ray, T. S. Chen, and C. J. McClain, “Efficacy of a transforming growth factor β2 containing nutritional support formula in a murine model of inflammatory bowel disease,” Journal of the American College of Nutrition, vol. 23, no. 3, pp. 220–226, 2004.
- S. T. Leach, H. M. Mitchell, W. R. Eng, L. Zhang, and A. S. Day, “Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 6, pp. 724–733, 2008.
- E. Pryce-Millar, S. H. Murch, and R. B. Heusckel, “Enteral nutrition therapy in Crohn's disease changes the mucosal flora,” Journal of Pediatric Gastroenterology and Nutrition, vol. 39, no. 1, p. S289, 2004.
- P. Lionetti, M. Callegari, and M. Cavicchi, “Enteral nutrition-induced remission is associated with profound modification of the intestinal microflora in Crohn's disease,” Journal of Pediatric Gastroentersology and Nutrition, vol. 39, p. S106, 2004.
- K. Madsen, A. Cornish, P. Soper et al., “Probiotic bacteria enhance murine and human intestinal epithelial barrier function,” Gastroenterology, vol. 121, no. 3, pp. 580–591, 2001.
- M. J. Medellin-Peña, H. Wang, R. Johnson, S. Anand, and M. W. Griffiths, “Probiotics affect virulence-related gene expression in Escherichia coli O157:H7,” Applied and Environmental Microbiology, vol. 73, no. 13, pp. 4259–4267, 2007.
- M. G. Gareau, J. Jury, G. MacQueen, P. M. Sherman, and M. H. Perdue, “Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation,” Gut, vol. 56, no. 11, pp. 1522–1528, 2007.
- L. de Ridder, E. H. H. M. Rings, G. M. Damen et al., “Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort,” Inflammatory Bowel Diseases, vol. 14, no. 3, pp. 353–358, 2008.
- A. M. F. Yee and M. B. Pochapin, “Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy,” Annals of Internal Medicine, vol. 135, no. 1, pp. 27–31, 2001.